Agile Therapeutics, Inc. (AGRX) financial statements (2021 and earlier)

Company profile

Business Address 101 POOR FARM ROAD
PRINCETON, NJ 08540-1715
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5434836493440
Cash and cash equivalents1434836493440
Short-term investments40      
Receivables1      
Inventory, net of allowances, customer advances and progress billings0      
Inventory0      
Prepaid expense1111341
Other undisclosed current assets(0)      
Total current assets:5735837523841
Noncurrent Assets
Operating lease, right-of-use asset0 
Property, plant and equipment14141414121212
Prepaid expense      2
Deferred costs     00
Other noncurrent assets2 00000
Other undisclosed noncurrent assets 0     
Total noncurrent assets:16141414121314
TOTAL ASSETS:73502251645155
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7424554
Accounts payable4213223
Accrued liabilities3211331
Employee-related liabilities      1
Debt 0 11525
Derivative instruments and hedges, liabilities   0000
Other undisclosed current liabilities0     (1)
Total current liabilities:742141189
Noncurrent Liabilities
Long-term debt and lease obligation    111310
Long-term debt, excluding current maturities    111310
Other undisclosed noncurrent liabilities16      
Total noncurrent liabilities:16   111310
Total liabilities:244214222119
Stockholders' equity
Stockholders' equity attributable to parent49462036423036
Common stock0000000
Additional paid in capital362306262258236194170
Accumulated other comprehensive income0      
Accumulated deficit(312)(260)(242)(222)(193)(165)(134)
Total stockholders' equity:49462036423036
TOTAL LIABILITIES AND EQUITY:73502251645155

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues1      
Cost of revenue(0)      
Gross profit:0      
Operating expenses(50)(19)(20)(27)(30)(33)(19)
Operating loss:(49)(19)(20)(27)(30)(33)(19)
Nonoperating income (expense)(3)0(1)(1)000
Investment income, nonoperating0000000
Interest and debt expense(3) (1)(2)(2)(3)(2)
Other undisclosed income from continuing operations before equity method investments, income taxes      0
Loss from continuing operations before equity method investments, income taxes:(55)(19)(21)(30)(32)(36)(20)
Other undisclosed income (loss) from continuing operations before income taxes3 120(0) 
Loss from continuing operations before income taxes:(52)(19)(20)(28)(32)(36)(20)
Income tax benefit  0 364
Net loss available to common stockholders, diluted:(52)(19)(20)(28)(29)(30)(16)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(52)(19)(20)(28)(29)(30)(16)
Comprehensive loss:(52)(19)(20)(28)(29)(30)(16)
Other undisclosed comprehensive income, net of tax, attributable to parent0      
Comprehensive loss, net of tax, attributable to parent:(52)(19)(20)(28)(29)(30)(16)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: